{"prompt": "['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'Section # and Name', 'Description of', 'Brief Rationale', 'Change', 'Clinical trial summary', 'To describe the Planned', 'To define a date for database lock when all randomized patients', 'Database lock', 'complete the week 52 visit or discontinue from the study before', 'week 52.', 'Clinical trial summary', 'To classify FeNO as a', 'Based on the strong pharmacodynamics effect of FeNO on', '9.3.1.3 Biomarker endpoints', 'secondary endpoint instead', 'QUEST, the Sponsor anticipates similar effect in this population', 'of an exploratory endpoint.', 'and feels appropriate to investigate it as secondary endpoint.', '9.4.1 Exploratory endpoints', '1.2 Study flow chart', 'To describe the fasting', 'Fasting status will be described as no intake of any food or drink', 'footnote y', 'status', 'except for water for at least 8 hours.', '9.2.3.5 Clinical Laboratory', 'Safety Variables', '1.2 Study Flow Chart;', 'To allow for home dosing', 'IMP home administration is allowed at any visit following Visit 9', 'footnote m', 'start after Visit 9', 'after parents have been trained and PI has allowed.', '8.1.4 Dosing schedule', 'Clinical trial summary', 'To clarify that ACQ 5 data', 'To clarify that ACQ 5 value at V2 shall be considered for the', '7.1 Inclusion Criteria', 'collected on V2 can be', 'evidence of uncontrolled asthma described in inclusion criterion', 'used for inclusion criterion', '01', '01', '9.2.2.4.1.1 ACQ-7-IA', 'To clarify how ACQ-7 value', 'To add the information that for statistical analysis, ACQ-7 global', '(Asthma Control', 'is calculated for statistical', 'score is calculated by sponsor using the BMS post central', 'Questionnaire-Interviewer', 'analysis', 'reading value for %predicted FEV1 for the question 7 of the', 'Administered, 7-question', 'questionnaire.', 'version)', '10.3.5 Procedure and', 'To remove a sentence on', 'To remove the sentence due to the change in Protocol template', 'Consequence for Patient', 'the possible hurdle to', 'Withdrawal from Study', 'public health value of the', 'study in case of study', 'withdrawal', 'Property of the Sanofi Group - strictly confidential', 'Page 7', 'VV-CLIN-0528583 6.0']['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'CLINICAL TRIAL SUMMARY', 'COMPOUND: Dupilumab', 'STUDY No.: EFC14153', 'TITLE', 'A randomized, double-blind, placebo-controlled, parallel group study to', 'evaluate the efficacy and safety of dupilumab in children 6 to <12 years of', 'age with uncontrolled persistent asthma.', 'INVESTIGATORITRIAL LOCATION', 'Worldwide', 'PHASE OF DEVELOPMENT', '3', 'STUDY OBJECTIVES', 'Primary objective:', 'The primary objective is to evaluate the efficacy of dupilumab in', 'children 6 to <12 years of age with uncontrolled persistent asthma', 'Secondary objectives:', 'To assess the safety and tolerability of dupilumab', 'To evaluate the effect of dupilumab in improving patient reported', 'outcomes (PROs) including health related quality of life (HRQoL)', 'To assess the dupilumab systemic exposure and incidence of', 'anti-drug antibodies (ADA).', 'To evaluate the association between dupilumab treatment and', 'pediatric immune responses to vaccines: any vaccination for', 'tetanus, diphtheria, pertussis and/or seasonal trivalent/quadrivalent', 'influenza vaccine', 'Exploratory objectives:', 'To explore baseline and on-treatment levels of biomarkers for their', 'potential to predict and to associate with a treatment response', 'To evaluate the proportion of patients requiring increased dose of', 'inhaled corticosteroids (ICS) or step up in the second controller', 'medication regimen.', 'To evaluate the effect of dupilumab on additional PROs', 'STUDY DESIGN', 'General Design', 'Multinational, multicenter, randomized, double-blind, placebo-controlled,', 'parallel-group study assessing the effect of dupilumab administered', 'subcutaneously (SC) for a maximum of 52 weeks in children 6 to <12 years of', 'age with uncontrolled asthma.', 'Periods', 'The clinical trial consists of three periods:', \"Screening Period (4 [+1] weeks) to determine a patient's eligibility\", 'status and establish level of asthma control before randomization', 'Treatment Period 52 weeks to treat with dupilumab or placebo SC', 'injection', \"Post-treatment Period 12 weeks to monitor a patient's status when\", 'off study drug treatment for patients who choose not to participate in', 'the 1-year long-term extension study', 'Property of the Sanofi Group - strictly confidential', 'Page 8', 'VV-CLIN-0528583 6.0']\n\n###\n\n", "completion": "END"}